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Abstract 
Administration of insulin for treatment of diabetes mellitus in dogs can stimulate an immune 
response, with a proportion of animals developing anti-insulin antibodies (AIA). For an IgG 
antibody response to occur, this would require B cell presentation of insulin peptides by major 
histocompatibility complex (MHC) class II molecules, encoded by dog leukocyte antigen 
(DLA) genes, in order to receive T-cell help for class switching. DLA genes are highly 
polymorphic in the dog population and vary from breed to breed. The aim of the present study 
was to evaluate AIA reactivity in diabetic dogs of different breeds and to investigate whether 
DLA genes influence AIA status. 
 
Indirect ELISA was used to determine serological reactivity to insulin in diabetic dogs, treated 
with either porcine or bovine insulin preparations. DLA haplotypes for diabetic dogs were 
determined by sequence-based typing of DLA-DRB1, -DQA1 and -DQB1 loci. Significantly 
greater insulin reactivity was seen in treated diabetic dogs (n = 942) compared with non-
diabetic dogs (n = 100). Of the diabetic dogs treated with a bovine insulin preparation, 52.3% 
(182/348) were AIA positive, compared with 12.6% (75/594) of dogs treated with a porcine 
insulin preparation, suggesting that bovine insulin is more immunogenic. Breeds such as 
dachshund, Cairn terrier, miniature schnauzer and Tibetan terrier were more likely to develop 
AIA, whereas cocker spaniels were less likely to develop AIA, compared with crossbreed dogs. 
In diabetic dogs, DLA haplotype DRB1*0015--DQA1*006--DQB1*023 was associated with 
being AIA positive, whereas the haplotype DLA-DRB1*006--DQA1*005--DQB1*007 showed 
an association with being AIA negative. These research findings suggest that DLA genes 
influence AIA responses in treated diabetic dogs. 
 
3 
 
Keywords: Diabetes mellitus; Dog breeds; Susceptibility genes; Dog leukocyte antigen; Major 
histocompatibility complex; Insulin 
4 
 
Introduction 
Diabetes mellitus is one of the most common endocrine disorders in dogs, with an estimated 
prevalence of 0.32% in the UK (Davison et al., 2005). It is a disease of middle to late age, with 
the majority of dogs diagnosed between 7 and 12 years old. It has been proposed that there are 
several potential underlying causes of diabetes in dogs, including immune mediated destruction 
of the beta cells of the pancreas, chronic pancreatitis and insulin resistance due to hormonal 
antagonism (Hoenig, 2002; Rand et al., 2004). Certain breeds of dog are predisposed to 
developing diabetes, which strongly suggests that there is a genetic component to disease 
susceptibility (Catchpole et al., 2008). Breeds such as the Samoyed, Tibetan terrier and Cairn 
terrier have an increased risk of developing diabetes, whereas other breeds, such as the Boxer 
and German Shepherd Dog have a reduced risk (Catchpole et al., 2005). 
 
Dog leukocyte antigen (DLA) genes, which encode MHC class II molecules, demonstrate 
considerable inter-breed variability (Kennedy et al., 2002) and have been linked with 
susceptibility to diabetes mellitus (Catchpole et al., 2008; Kennedy et al., 2006). Three DLA 
haplotypes in particular, DLA-DRB1*009--DQA1*001--DQB1*008, DRB1*015--DQA1*006-
-DQB1*023 and DRB1*002--DQA1*009--DQB1*001, have been shown to be associated with 
susceptibility to diabetes and are prevalent in the Samoyed, Tibetan terrier and Cairn terrier 
breeds. 
 
Virtually all diabetic dogs require insulin by injection to control their hyperglycaemia, but this 
can stimulate an immune response and some dogs develop anti-insulin antibodies (AIA) 
following initiation of therapy (Davison et al., 2003). A previous study showed that around 
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60% of dogs treated with Insuvet lente (Intervet / Pfizer Animal Health), a bovine insulin 
preparation, developed AIA, whereas only around 10% of dogs treated with Caninsulin (MSD 
Animal Health), a porcine insulin preparation, developed AIA (Davison et al., 2008). This 
suggests that bovine insulin is more immunogenic than porcine insulin, which is likely due to 
variation of the insulin sequence between species (Fineberg et al., 2007); the amino acid 
sequence is the same comparing porcine and canine insulin, but bovine insulin differs from 
canine insulin by two amino acids in the A chain (Davison et al., 2003). Although bovine 
insulin seems to be more immunogenic in dogs, the AIA that develop are not species specific 
as they react with both porcine and bovine insulin in ELISA and typically recognise 
conformational, rather than linear epitopes (Davison et al., 2003). 
 
Generation of an immunoglobulin (Ig)G antibody response to a foreign protein requires B cells 
to process antigen and present digested peptide fragments, bound to MHC class II molecules, 
to recruit T cell help. Polymorphisms in MHC class II genes influence the structure of the 
peptide-binding groove and therefore the repertoire of antigenic peptides that can be presented 
to the immune system. Considering the small size of the insulin molecule, it is likely that there 
are limited peptide epitopes available for presentation, suggesting that MHC class II genes 
could play a major role in whether an anti-insulin response is initiated or not (Fineberg et al., 
2007). In humans, differences in AIA production have been associated with particular human 
leukocyte antigen (HLA) types (Reeves et al., 1984; Schernthaner et al., 1979; Sklenar et al., 
1982) and in mice the presence of specific H-2 linked immune response genes for insulin has 
been demonstrated (Kapp and Strayer, 1978). 
 
The aim of the present study was to further evaluate AIA in diabetic dogs, treated with different 
insulin preparations, to determine whether there were breed differences in AIA reactivity and 
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to evaluate whether there was any evidence for a DLA genetic influence on AIA responses in 
diabetic dogs. 
 
Materials and methods 
Blood samples 
Blood samples (serum and EDTA blood) from diabetic dogs were collected between 2002 and 
2010 as part of the UK Canine Diabetes Register at the Royal Veterinary College. This archive 
was established with institutional ethical approval, by recruiting blood samples from diabetic 
dogs seen by first opinion veterinary practices and referral centres throughout the UK, with 
informed owner consent. The population used in this study consisted of 109 recently diagnosed 
and untreated diabetic dogs, 594 diabetic dogs treated with Caninsulin (MSD Animal Health) 
and 348 dogs treated with Insuvet lente (Intervet and latterly Pfizer Animal Health). Diabetic 
dogs in the insulin-treated groups had been receiving insulin therapy for more than 30 days. 
One hundred control serum samples were obtained from non-diabetic dogs referred to the 
Queen Mother Hospital for Animals at the Royal Veterinary College, following completion of 
diagnostic testing, with informed owner consent for residual samples to be used in clinical 
research. 
 
ELISA procedure 
Measurement of AIA in diabetic and control serum samples was performed by indirect ELISA, 
as described previously (Davison et al., 2008). Briefly, flat bottomed 96 well microtitre plates 
(Maxisorp, Nunc) were coated with porcine insulin (Sigma-Aldrich) at 10 µg/mL in 0.05 M 
carbonate/ bicarbonate buffer, pH 9.6 (Sigma-Aldrich) overnight at 4 °C. All washing steps 
were performed with phosphate buffered saline (Invitrogen) supplemented with 0.1% tween 20 
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(Sigma-Aldrich) (PBST). Plates were blocked with PBST supplemented with 2% skimmed 
milk (Marvel, Premier beverages) and 10% rabbit serum (Sigma-Aldrich). Serum was added 
in duplicate wells, diluted 1:100 in PBST supplemented with 1% skimmed milk and 10% rabbit 
serum. Antibody binding was detected using a rabbit anti-canine IgG HRP conjugate (Stratech 
Scientific) diluted 1:10,000 in PBST supplemented with 1% milk and 10% rabbit serum. Plates 
were developed using 3,3ʹ,5,5ʹ-tetramethylbenzidine substrate (TMB slow kinetic form, 
Sigma-Aldrich), which was incubated for 1–2 min before reactions were stopped using 2 M 
sulphuric acid (Scientific Laboratory Supplies). The optical density was measured at 450 nm 
(OD450nm) using a SpectraMAX M2 plate reader (Molecular Devices). 
 
ELISA data analysis 
Results for each serum sample were calculated as the mean OD450nm for anti-insulin reactivity 
minus the background (obtained from wells coated with 50 µL 0.05 M carbonate/bicarbonate 
buffer without insulin). A positive control serum sample identified in a pilot study was used in 
all subsequent ELISA to allow for correction of inter-assay variability. This was used to 
calculate a correction factor, which was applied to normalise all OD450nm values on each plate. 
A threshold for positive reactivity was set using non-diabetic control samples. A minimum 
threshold of mean + 1.96× SD was used. 
 
Sequence-based typing 
Diabetic dogs were characterised for three MHC class II loci DLA-DRB1, -DQA1 and –DQB1, 
using sequence-based typing. Genomic DNA was extracted from EDTA blood samples using 
the QIAamp DNA Blood Midi Kit (Qiagen), according to the manufacturer’s instructions. 
Polymerase chain reaction (PCR) was performed with 25 ng genomic DNA in a 25 µL reaction 
containing 1× PCR buffer, Q solution, 200 µM each dNTP, 2.5 units HotStarTaq DNA 
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polymerase (all from Qiagen) and primers at a final concentration of 0.1 µM each. The primers 
used were DLA-DRBIn1forward: 5ʹ-CCG TCC CCA CAG CAC ATT TC-3ʹ, DLA-DRBIn2-
T7 reverse: 5ʹ-TAA TAC GAC TCA CTA TAG GG TGT GTC ACA CAC CTC AGC ACC 
A-3ʹ, DLA-DQAIn1forward: 5ʹ-TAA GGT TCT TTT CTC CCT CT-3ʹ, DLA-DQAIn2 
reverse: 5ʹ-GGA CAG ATT CAG TGA AGA GA-3ʹ, DLA-DQB1B-T7 forward: 5ʹ-TAA TAC 
GAC TCA CTA TAG GG CTC ACT GGC CCG GCT GTC TC-3ʹ and DLA-DQBR2 reverse: 
5ʹ-CAC CTC GCC GCT GCA ACG TG-3ʹ. All primers were intronic and locus specific, and 
produced amplicons of 303 bp (DRB1), 345 bp (DQA1) and 300 bp (DQB1). A standard 
touchdown PCR protocol was employed for all amplifications. This consisted of an initial 
activation at 95°C for 15 min, then 14 touchdown cycles of 95°C for 30 s (denaturation), a 1 
min annealing step starting at 62°C (DRB1), 54°C (DQA1), 73°C (DQB1) and reducing by 
0.5°C each cycle, and an elongation step at 72°C for 1 min. This was followed by 20 cycles of 
95°C for 30 s, 55°C (DRB1), 47°C (DQA1) and 66°C (DQB1) for 1 min, 72°C for 1 min and 
a final extension at 72°C for 10 min. 
 
Prior to sequencing, the presence of a product was checked by agarose gel electrophoresis, and 
PCR products were purified by adding 2 units of shrimp alkaline phosphatase (Amersham 
Biosciences) and 10 units of Exonuclease1 (New England Biolabs) to 5 µL of PCR product. 
The mixture was incubated for 1 h at 37°C and then for 15 min at 80°C. Sequencing reactions, 
using a T7 primer for DLA-DRB1 and DQB1, and DQAIn2 reverse primer for DLA-DQA1, 
were performed using Big Dye Terminator V3 (Life Technologies). Samples were sequenced 
on an Applied Biosystems 373 Genetic Analyser and sequencing data was analysed using 
SBTengine (GenDX). 
 
9 
 
Statistical analysis 
Statistical analyses were performed using commercial software package (SPSS version 18 for 
Windows, IBM). Anti-insulin antibody reactivity in control and diabetic groups was compared 
using Kruskal-Wallis test, which if significant was followed by multiple Mann-Whitney U tests 
with a Bonferroni correction applied. Anti-insulin antibody status in different breeds of dog 
was examined using Fisher’s exact test to compare the ratio of AIA negative and AIA positive 
dogs in each pedigree breed with the cross breed population. Odds ratios were calculated to 
compare DLA haplotype frequencies between AIA negative and positive diabetic dogs, 
Fisher’s exact test was then used to determine whether the differences were significant. 
 
Results 
Anti-insulin antibodies (AIA) were measured by ELISA in serum samples from 100 control 
dogs, 109 newly diagnosed diabetic dogs and 942 treated diabetic dogs. Of the treated diabetic 
dogs, 594 had received treatment with Caninsulin and 348 others had received Insuvet lente. 
The threshold for positive AIA reactivity was to be set using the 95% confidence interval of 
the control population (mean OD450nm  1.96× SD); however, since the control dogs were all 
found to have negligible anti-insulin reactivity (mean OD450nm = 0.001; SD = 0.005), an 
arbitrary ELISA absorbance value of 0.1 was used as the threshold for AIA positivity (Figure 
1A). There was a significant difference in AIA reactivity comparing newly diagnosed diabetic 
dogs and control dogs (P = 0.02), with three of the 109 newly diagnosed diabetic dogs classified 
as positive for AIA (Figure 1A). Anti-insulin reactivity in the treated diabetic dogs was 
significantly greater than in control and newly diagnosed diabetic dogs (P <0.001). Diabetic 
dogs treated with bovine insulin demonstrated significantly greater AIA reactivity than dogs 
treated with porcine insulin (P < 0.001). In dogs treated with porcine insulin, 12% (75/594) 
were AIA positive, compared with 52% (182/348) of dogs treated with bovine insulin (Fig. 
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1B). Although the cases and controls were not entirely aged matched, age was not found to be 
an influencing factor on the development of AIA, since treated diabetic dogs that were AIA 
positive were of a similar age (mean = 9.9 years; range 0.4–17.6 years) to those that were AIA 
negative (mean = 10.1 years; range 1.0–16.3 years). 
Upon submission of samples to the UK Canine Diabetes Register veterinary practitioners were 
asked to provide information for each dog relating to insulin dose, frequency and duration of 
treatment. Fructosamine concentrations were measured in serum samples to provide 
information on glycaemic control. For each of these variables, comparisons were made 
between AIA negative and AIA positive dogs for the type of insulin treatment used. Since, 
information was lacking for some dogs, a smaller population was taken forward for this 
analysis (Table 1). 
The majority of diabetic dogs (731/914) were receiving twice daily injections of insulin, with 
the remainder receiving once daily injections. Dogs receiving once daily insulin were receiving 
greater insulin doses per injection than those treated twice daily (Table 1). There was also a 
trend for dogs who had developed AIA to be receiving greater insulin doses than those who 
were AIA negative, but this was only significant in dogs treated with the bovine insulin product 
(P = 0.017). The duration of insulin treatment varied greatly within the diabetic population, but 
there appeared to be no relationship between duration of insulin treatment and the AIA status 
(Table 1). Fructosamine values were similar, comparing the different treatment groups, with 
no significant difference between groups (Table 1). 
 
Within the population of diabetic dogs treated with either Caninsulin or Insuvet lente, AIA 
status was assessed, comparing different dog breeds. Breed differences were seen in terms of 
the antibody response to insulin treatment (Figures 2A, B). Breeds such as miniature schnauzer 
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and Tibetan terrier were found to be relatively susceptible to developing AIA, when treated 
with either insulin preparation. The dachshund and Cairn terrier were found to be more likely 
to develop AIA when treated with Insuvet lente, when compared with crossbreed dogs. Cocker 
spaniels were relatively resistant to developing AIA when treated with insulin, compared with 
other breeds. The Samoyed breed was unusual, in that treatment with Caninsulin was found to 
stimulate AIA in a greater proportion of dogs, compared with crossbreed dogs, but the 
proportion of AIA positive dogs was similar to that seen in other breeds when Insuvet lente 
was used.  
 
Genomic DNA was extracted from EDTA blood samples from diabetic dogs and DLA 
genotyping was performed. Not all the dogs that had been assayed for AIA had an EDTA 
sample available, so a smaller population of dogs was used for this analysis. After DLA 
genotyping the diabetic dog population, the data were grouped according to insulin type and 
AIA status (Table 2;  Table 3). DRB1*0015:01--DQA1*006:01--DQB1*023:01 was found to 
be associated with being AIA positive in dogs treated with porcine insulin, whereas 
DRB1*006:01--DQA1*005:011--DQB1*007:01 was found to be associated with being AIA 
negative in both porcine and bovine insulin treated diabetic dogs. The intention was to evaluate 
the relationship between AIA status and DLA-type in several breeds, but only Labrador 
retrievers had sufficient numbers of dogs of defined haplotypes to be able to perform this 
analysis in a robust way (Table 4; Table 5). DLA-DRB1*001:01--DQA1*001:01--
DQB1*002:01 was found to be associated with being AIA negative in Labrador retrievers 
treated with bovine insulin. 
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Discussion 
This study was designed to investigate anti-insulin antibodies in diabetic dogs, and to examine 
the influence that breed and DLA genes might have on the antibody responses elicited by 
insulin therapy. Porcine insulin was selected as the antigen for use in ELISA as it had been 
shown previously that there was a high correlation between AIA reactivity measured against 
bovine or porcine insulin and that there was antibody cross-reactivity between these two insulin 
types (Davison et al., 2003) 
 
Control dogs demonstrated negligible AIA reactivity, which might be expected since they have 
not been exposed to the antigen, over and above that present physiologically. However, a 
previous study reported AIA in 4 of 120 control dogs (Davison et al., 2008). This latter finding 
might represent false positives in the insulin ELISA, or might be due to the presence of insulin 
autoantibodies in dogs that were potentially in a pre-diabetic state. Insulin autoantibodies are 
associated with the development of diabetes in NOD mice (Abiru et al., 2001) and in humans 
their presence has been shown to be predictive for diabetes when used in conjunction with other 
islet-cell antibodies (Franke et al., 2005). In the present study, 3 of 109 newly diagnosed 
diabetic dogs were positive for AIA, suggesting that insulin autoantibodies might be present as 
a component of the disease process, but that these are relatively uncommon. 
 
Anti-insulin antibody reactivity in diabetic dogs treated with Insuvet lente was significantly 
greater than that seen in Caninsulin-treated dogs, where 52% of Insuvet lente-treated dogs were 
AIA positive, compared with 12% of dogs receiving Caninsulin. These findings are consistent 
with a previous study in a much smaller sample population (Davison et al., 2008). This 
difference in anti-insulin antibody response is likely due to the fact that bovine insulin (Insuvet 
lente) differs from canine insulin by two amino acids and would be seen by the host immune 
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system as foreign antigen, whereas porcine insulin (Caninsulin) has an identical amino acid 
sequence compared with canine insulin, so should be less immunogenic. However, if this was 
the only factor affecting the AIA response, it might be expected that all dogs treated with 
Insuvet lente would be AIA positive and all dogs treated with Caninsulin would be AIA 
negative. Since this is not the case, host immune factors must also play a role in determining 
the immunological outcome (tolerance or activation) when dogs receive insulin therapy. 
 
The development of an antibody response to self or harmless environmental antigen is usually 
prevented by several tolerance mechanisms. Although B cell tolerance is not particularly 
robust, class switching to IgG and production of high antibody titres are dependent upon the 
presence of CD4+ T-helper cells. Central tolerance to self-antigens is established by clonal 
deletion of T cells during their development in the thymus. In humans, insulin expression in 
the thymus is influenced by a variable number of tandem repeats (VNTR) in the insulin gene 
promoter (Pugliese et al., 1997; Vafiadis et al., 1997). Long VNTR alleles (140-210 repeats), 
have been shown to confer resistance to diabetes which is associated with higher levels of 
insulin mRNA expression in the thymus compared to short VNTR alleles (26-63 repeats), 
which predispose to diabetes. This suggests that the higher levels of insulin expression 
associated with the long INS VNTR alleles allow induction of immune tolerance and so protects 
against the development of diabetes caused by auto reactive T cells. In dogs, no equivalent 
VNTR has been found in the canine insulin gene promoter, although one has been identified in 
intron 2 of the gene (Catchpole et al., 2013). However, this location in the insulin gene means 
that it is unlikely to have the same effect on expression of canine insulin and induction of 
immunological tolerance. 
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Peripheral tolerance mechanisms become important, once T cells have left the thymus and enter 
the circulation, migrating through the various secondary lymphoid tissues. Clonal ignorance 
can occur when antigen is presented at a level insufficient to stimulate an immune response. 
Since expression of insulin in the periphery is restricted to the beta cells of the pancreas and 
insulin in the circulation has a relatively short half-life (Duckworth et al., 1998), it is possible 
that the immune system’s exposure to insulin as an antigen fails to reach the threshold for 
lymphocyte activation. Other forms of peripheral tolerance include T cell anergy, when antigen 
is presented without the presence of co-stimulatory molecules, and active suppression, 
mediated by regulatory T cells. 
 
In dogs treated with porcine insulin that develop AIA, it is possible that there has been a failure 
to establish tolerance to insulin, and immune activation occurs when an exogenous insulin 
preparation is administered. In contrast, Insuvet lente-treated dogs who fail to develop AIA are 
presumably already tolerant to insulin (by central and/or peripheral tolerance mechanisms) or 
establish tolerance after repeated injection of exogenous foreign insulin. A previous study has 
shown that dogs treated with an escalating dose of mixed bovine-porcine insulin failed to 
produce an anti-insulin antibody response (Menzel et al., 1971), which might be related to 
induction of anergy in insulin-specific naïve T cells or stimulation of regulatory T cells. 
 
The duration of insulin treatment did not appear to have an effect on the presence or absence 
of AIA (Table 1). A previous study found that dogs varied in their AIA response over time 
(Davison et al., 2008). In some cases, AIA were produced within 3 months of initiating insulin 
therapy, reaching a plateau at around 6 months. However, there were some individuals who 
showed no evidence of insulin reactivity during the first year of treatment. A similar pattern 
has also been observed in human diabetic patients (Reeves and Kelly, 1982). 
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The majority of diabetic dogs were receiving twice daily insulin injections and were generally 
on a lower dose per kg per injection than those receiving once daily insulin therapy (Table 1). 
Twice daily therapy has been shown to provide better glycaemic control than once daily insulin 
administration (Hess and Ward, 2000). Dogs receiving once daily injections of bovine insulin, 
that were AIA positive, were more likely to be receiving higher doses of insulin, compared 
with those that were AIA negative. It is possible that exposure to greater amounts of insulin 
per injection influences the magnitude of the antibody response. Alternatively, it is feasible 
that the AIA are having a partial neutralising effect on insulin activity, which would therefore 
require higher doses of insulin to maintain glycaemic control. In human diabetic patients, it has 
been shown that high levels of circulating AIA can affect the dose of insulin required to 
maintain glycaemic control and that by changing to a less immunogenic insulin there is a 
reduction in AIA and the dose of insulin required by the patient (Walford et al., 1982). 
 
Measurement of serum fructosamine is routinely used to evaluate glycaemic control in diabetic 
dogs (Webb, 2002). Fructosamine values were similar and not significantly different 
comparing the different insulin treatment groups and comparing dogs of different AIA status. 
This suggests that the presence of AIA does not substantially influence glycaemic control per 
se, although this might be one factor to consider in an individual unstable diabetic dog, where 
insulin resistance is suspected. 
 
Different breeds of dog were found to vary in their immune response to insulin therapy. Breeds 
such as the miniature schnauzer and Tibetan terrier were found to be relatively susceptible to 
developing AIA, whereas Cocker spaniels were found to be less likely to develop AIA when 
treated with insulin. Samoyed dogs were relatively susceptible to developing AIA when treated 
with Caninsulin, but were no more likely to do so, compared with other breeds, when treated 
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with Insuvet lente. This was unexpected since this suggests that self-insulin is as immunogenic 
as foreign insulin in this particular breed. Samoyeds are one of the most diabetes-susceptible 
dog breeds in the UK (Catchpole et al., 2005) and this research finding might be consistent 
with an autoimmune pathogenesis. 
 
These differences in AIA reactivity, comparing dog breeds, suggest that genetic factors might 
influence the immune response to insulin. Different strains of mice have been shown to vary 
in their immune response to insulin and this is believed to be controlled by the H-2 linked 
immune response (Ir) genes of the MHC (Kapp and Strayer, 1978; Keck, 1975). In mice 
immunised with porcine or bovine insulin, those with the H-2b haplotype respond only to 
porcine insulin, whereas those with the H-2d haplotype respond to both types. H-2b mice 
present epitopes from the insulin A-chain, which differs between porcine and bovine insulin 
by two amino acids, whereas H-2d mice present insulin B-chain epitopes, which are identical 
in porcine and bovine insulin (Keck, 1975; Rosenwasser et al., 1979). 
 
The current study examined the possibility that polymorphisms in DLA genes might influence 
antigen presentation and therefore immune responses to insulin in dogs. Two DLA haplotypes 
showed an association with AIA status. DRB1*0015:01--DQA1*006:01--DQB1*023:01 was 
associated with being AIA positive in Caninsulin-treated dogs, whereas DRB1*006:01--
DQA1*005:011--DQB1*007:01 showed an association with being AIA negative regardless of 
the insulin type used, suggesting that some DLA-types do influence AIA responses in treated 
diabetic dogs. The haplotype that was associated with development of AIA has also been shown 
to be associated with overall susceptibility to diabetes in dogs (Kennedy et al., 2006), 
suggesting it might play a role in presentation of pancreatic auto-antigens (including insulin) 
involved in the pathogenesis of the disease. The haplotype which is associated with being 
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negative for AIA is one which is commonly found in Cocker spaniels. This suggests that either 
this MHC haplotype is unable to present insulin epitopes or, alternatively, that it can present 
insulin peptides, but that this leads to efficient tolerance mechanisms preventing an antibody 
response from being stimulated. Peptide binding studies using purified canine MHC molecules, 
similar those undertaken for HLA-DR (O'Sullivan et al., 1990) and HLA-DQ (Kwok et al., 
1995), could potentially be used to investigate this further. 
 
The associations between DLA and AIA status that were seen in the diabetic population as a 
whole were not evident in Labrador retrievers, although when stratified according to AIA status 
and DLA-type, the numbers of dogs in each category were relatively low. The DLA haplotype 
DRB1*001:01--DQA1*001:01--DQB1*00201 showed an association with being AIA negative 
in Insuvet lente-treated diabetic Labradors, suggesting that some associations between DLA 
and AIA reactivity might be breed specific or that other genes are also involved in determining 
whether AIA develop or not. 
 
Conclusion 
The current study has demonstrated that treatment of diabetic dogs with Insuvet lente was more 
likely to stimulate an AIA response compared with treatment using Caninsulin. Both breed of 
dog and DLA haplotype were found to influence the development of AIA, suggesting that 
genetic factors are involved in determining whether a dog will make an immune response to 
insulin during therapy. 
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Table 1. Data relating to insulin therapy and glycaemic control in AIA negative and 
positive dogs. 
 
Insulin dose SID 
treatment 
(IU/kg/injection) 
Insulin dose 
BID treatment 
(IU/kg/injection) 
Duration of 
treatment (months) 
Fructosamine 
(μmol/L) 
Porcine 
insulinAIA 
negative 1.08[0.29–4.07]n = 80 
0.70[0.04–
2.61]n = 408 
8.60[1–78.4]n = 
515 
477.5[189–992]n = 
464 
Porcine 
insulinAIA 
positive 1.33[0.46–3.27]n = 13 
0.71[0.33–
1.56]n = 58 
9.55[1.2–81.4]n = 
74 
491.5[216–940]n = 
70 
Bovine 
insulinAIA 
negative 1.05*[0.43–4.6]n = 40 
0.82[0.29–
2.72]n = 106 
10.60[1–104.2]n = 
162 501[204–903]n = 131 
Bovine 
insulinAIA 
positive 1.40*[0.55–3.17]n = 39 
0.87[0.12–
2.78]n = 127 
7.55[1.3–59.0]n = 
182 512[247–940]n = 145 
Data is shown as the median, [range] and number of cases (n). SID = once daily. BID = twice daily. Data significantly 
associated with AIA status is shown in bold (*P < 0.05). 
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Table 2. DLA haplotypes in diabetic dogs treated with Caninsulin in relation to AIA 
status 
DLA haplotype a 
AIA negative AIA positive 
OR P value Number Frequency (%) Number Frequency (%) 
001:01--001:01--002:01 115 14.97 12 10.34 0.690 NS 
001:01--001:01--036:01 18 2.34 1 0.86 0.367 NS 
001:01--003:01--004:01 5 0.65 2 1.72 2.646 NS 
001:01--009:01--001:01 24 3.12 2 1.72 0.551 NS 
002:01--009:01--001:01 52 6.77 4 3.44 0.506 NS 
006:01--004:01--013:03 5 0.65 0 0 0 NS 
006:01--005:011--007:01 97 12.63 7 6.03 0.477 0.043 
006:01--005:011--020:01 13 1.69 1 0.86 0.509 NS 
008:02--003:01--004:01 7 0.91 0 0 0 NS 
009:01--001:01--008:02 56 7.29 9 7.75 1.063 NS 
011:01--002:01--013:02 16 2.08 0 0 0 NS 
011:01--002:01--013:03 9 1.17 1 0.86 0.735 NS 
012:01--004:01--013:03 8 1.04 2 1.72 1.653 NS 
012:01--004:01--013:017 32 4.16 11 9.48 2.279 NS 
013:01--001:01--002:01 26 3.38 2 1.72 0.509 NS 
015:01--006:01--003:01 11 1.43 2 1.72 1.203 NS 
015:01--006:01--011:01 7 0.91 0 0 0 NS 
015:01--006:01--019:054 9 1.17 6 5.17 4.419 NS 
015:01--006:01--020:02 30 3.91 4 3.44 0.880 NS 
015:01--006:01--022:01 8 1.04 0 0 0 NS 
015:01--006:01--023:01 68 8.85 22 18.97 2.144 0.0015 
015:01--009:01--001:01 16 2.08 0 0 0 NS 
015:02--006:01--023:01 45 5.85 13 11.21 1.916 NS 
018:01--001:01--002:01 8 1.04 1 0.86 0.827 NS 
018:01--001:01--008:02 13 1.69 3 2.58 1.527 NS 
020:01--004:01--013:03 29 3.77 3 2.58 0.684 NS 
023:01--003:01--005:01 7 0.91 0 0 0 NS 
040:01--010:01--019:01 5 0.65 0 0 0 NS 
Other haplotypes 29 3.78 8 6.98   
Total number 768  116    
 
a DLA haplotype for DRB1*--DQA1*--DQB1*. OR, odds ratio; NS, not significant. P values were calculated 
using Fisher’s exact test. DLA haplotypes significantly associated with AIA status are shown in bold. 
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Table 3. DLA haplotypes in diabetic dogs treated with Insuvet lente in relation to AIA 
status. 
DLA haplotype a 
AIA negative AIA positive 
OR P value Number Frequency (%) Number Frequency (%) 
001:01--001:01--002:01 27 9.44 37 11.14 1.180 NS 
001:01--001:01--036:01 1 0.35 7 2.11 6.030 NS 
001:01--003:01--004:01 1 0.35 7 2.11 6.030 NS 
001:01--009:01--001:01 3 1.05 4 1.20 1.143 NS 
002:01--009:01--001:01 19 6.64 19 5.72 0.861 NS 
006:01--004:01--013:03 4 1.40 9 2.71 1.936 NS 
006:01--005:011--007:01 43 15.03 22 6.63 0.441 0.0009 
006:01--005:011--020:01 2 0.70 4 1.20 1.714 NS 
008:02--003:01--004:01 2 0.70 3 0.90 1.286 NS 
009:01--001:01--008:02 14 4.90 30 9.04 1.845 NS 
011:01--002:01--013:02 4 1.40 3 0.90 0.643 NS 
011:01--002:01--013:03 7 2.45 4 1.20 0.490 NS 
012:01--004:01--013:03 4 1.40 4 1.20 0.857 NS 
012:01--004:01--013:017 16 5.59 15 4.52 0.809 NS 
013:01--001:01--002:01 16 5.59 11 3.31 0.592 NS 
015:01--006:01--003:01 1 0.35 6 1.81 5.171 NS 
015:01--006:01--011:01 1 0.35 4 1.20 3.429 NS 
015:01--006:01--019:054 11 3.85 6 1.81 0.470 NS 
015:01--006:01--020:02 9 3.15 6 1.81 0.575 NS 
015:01--006:01--022:01 3 1.05 8 2.41 2.295 NS 
015:01--006:01--023:01 34 11.89 47 14.16 1.191 NS 
015:01--009:01--001:01 1 0.35 5 1.51 4.314 NS 
015:02--006:01--023:01 13 4.55 28 8.43 1.853 NS 
018:01--001:01--002:01 8 2.80 2 0.60 0.214 NS 
018:01--001:01--008:02 6 2.10 1 0.30 0.143 NS 
020:01--004:01--013:03 10 3.50 9 2.71 0.774 NS 
023:01--003:01--005:01 5 1.75 3 0.90 0.514 NS 
040:01--010:01--019:01 2 0.70 4 1.20 1.714 NS 
Other haplotypes 19 6.64 24 7.23   
Total number 286  332    
 
a DLA haplotype for DRB1*--DQA1*--DQB1*. OR, odds ratio; NS, not significant. P values were calculated 
using Fisher’s exact test. DLA haplotypes significantly associated with AIA status are shown in bold. 
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Table 4. DLA haplotypes in diabetic Labrador retrievers treated with Caninsulin in 
relation to AIA status. 
DLA haplotype a 
AIA negative AIA positive 
OR P value Number Frequency (%) Number Frequency (%) 
001:01--001:01--002:01 17 25.76 1 5.26 0.204 NS 
002:01--009:01--001:01 1 1.52 0 0 0 NS 
006:01--005:011--007:01 5 7.57 2 10.53 1.391 NS 
006:01--005:011--020:01 5 7.57 0 0 0 NS 
008:02--003:01--004:01 1 1.52 0 0 0 NS 
009:01--001:01--008:02 0 0 1 5.26 0 NS 
012:01--004:01--013:017 18 27.27 7 36.84 1.351 NS 
012:01--004:01--013:03 1 1.52 1 5.26 3.460 NS 
015:01--006:01--023:01 11 16.67 2 10.53 0.632 NS 
015:02--006:01--023:01 6 9.09 4 21.05 2.316 NS 
020:01--004:01--013:03 1 1.52 1 5.26 3.460 NS 
Total number 66  19    
 
a DLA haplotype for DRB1*--DQA1*--DQB1*. OR, odds ratio; NS, not significant. P values were calculated 
using Fisher’s exact test. DLA haplotypes significantly associated with AIA status are shown in bold. 
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Table 5. DLA haplotypes in diabetic Labrador retrievers treated with Insuvet lente in 
relation to AIA status. 
DLA haplotype a 
AIA negative AIA positive 
OR P value Number Frequency (%) Number Frequency (%) 
001:01--001:01--002:01 10 23.81 1 2.63 0.110 0.008 
001:01--001:01--036:01 0 0 1 2.63 0 NS 
006:01--005:011--007:01 9 21.43 5 13.16 0.614 NS 
006:01--005:011--020:01 1 2.38 1 2.63 0 NS 
008:02--003:01--004:01 1 2.38 2 5.26 2.210 NS 
011:01--002:01--013:01 0 0 1 2.63 0 NS 
012:01--004:01--013:017 10 23.81 11 28.95 1.216 NS 
012:01--004:01--013:03 0 0 2 5.26 0 NS 
012:01--001:01--002:01 0 0 1 2.63 0 NS 
013:01--001:01--002:01 0 0 1 2.63 0 NS 
015:01--006:01--023:01 3 7.14 4 10.53 1.475 NS 
015:02--006:01--023:01 6 14.29 6 15.79 1.105 NS 
019:01--004:01--013:03 1 2.38 0 0 0 NS 
020:01--004:01--013:03 1 2.38 2 5.26 2.210 NS 
Total number 42  38    
 
a DLA haplotype for DRB1*--DQA1*--DQB1*. OR, odds ratio; NS, not significant. P values were calculated 
using Fisher’s exact test. DLA haplotypes significantly associated with AIA status are shown in bold. 
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Fig. 1. Anti-insulin antibodies in diabetic and control dogs. (A) Anti-insulin antibodies 
(AIA) were measured by ELISA in serum samples from 100 control dogs, 109 newly diagnosed 
diabetic dogs and 992 diabetic dogs treated with either Caninsulin or Insuvet lente. Each data 
point represents the normalised ELISA absorbance value for each serum sample and the line 
represents the threshold for AIA positivity (OD450nm = 0.1). P values were calculated using 
Mann-Whitney U tests with a Bonferroni correction. *P <0.05; **P <0.001. (B) Bar chart 
showing the proportion of diabetic dogs positive or negative for AIA in the different treatment 
groups. 
 
 
Fig. 2. Anti-insulin antibody reactivity in different dog breeds. Diabetic dogs treated with 
(A) Caninsulin or (B) Insuvet lente were grouped according to breed and AIA status. P values 
were generated using Fishers exact test to compare each pedigree breed with the reference 
cross-breed population. *P <0.05, **P <0.01. 
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